Acambis maintained by Merrill at neutral

Acambis plc was maintained by Merrill Lynch analyst Peter Welford at a neutral rating following the company's announcement of launching two new influenza vaccine trials. Acambis shares in London gained 9p, or 3.91%, to 239p on volume of 1,400,673 shares versus the three-month running average of 162,779 shares. In the United States, the shares gained $0.39, or 4.60%, to close at $8.86 on volume of 52,280 shares versus the three-month running average of 17,012.3 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.